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Summary
 
In this study we describe oxazolone colitis, a new form of experimental colitis. This model is
induced in SJL/J mice by the rectal instillation of the haptenating agent, oxazolone, and is
characterized by a rapidly developing colitis confined to the distal half of the colon; it consists
of a mixed neutrophil/lymphocyte infiltration limited to the superficial layer of the mucosa
which is associated with ulceration. Oxazolone colitis is a T helper cell type 2 (Th2)-mediated
process since stimulated T cells from lesional tissue produce markedly increased amounts of in-
terleukin (IL)-4 and IL-5; in addition, anti–IL-4 administration leads to a striking amelioration
of disease, whereas anti–IL-12 administration either has no effect or exacerbates disease. Fi-
nally, this proinflammatory Th2 cytokine response is counterbalanced by a massive transform-
ing growth factor-
 
b
 
 (TGF-
 
b
 
) response which limits both the extent and duration of disease: le-
sional (distal) T cells manifest a 20–30-fold increase in TGF-
 
b
 
 production, whereas nonlesional
(proximal) T cells manifest an even greater 40–50-fold increase. In addition, anti–TGF-
 
b
 
 ad-
ministration leads to more severe inflammation which now involves the entire colon. The his-
tologic features and distribution of oxazolone colitis have characteristics that resemble ulcer-
ative colitis (UC) and thus sharply distinguish this model from most other models, which
usually resemble Crohn’s disease. This feature of oxazolone colitis as well as its cytokine profile
have important implications to the pathogenesis and treatment of UC.
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apten-induced experimental colitis in mice (i.e.,
TNBS
 
1
 
 colitis induced by the haptenating agent,
2,4,6-trinitrobenzene sulfonic acid) has proven to be an ex-
ceptionally useful model of certain forms of human inflam-
matory bowel disease. For example, the study of this model
has led to the recognition that an IL-12–driven, Th1 T
cell–mediated inflammation of the colon is not only pre-
vented by the systemic administration of anti–IL-12 anti-
body, but can also be treated by such administration (1).
This observation has provided the theoretical justification
for the use of inhibitors of IL-12, including anti–IL-12 it-
self, in the treatment of Crohn’s disease, an inflammation
also dominated by a Th1 T cell response (2–5). Studies of
the TNBS colitis model have also shown that administra-
tion of TNBS per rectum and per os have very different ef-
fects; rectal administration results in severe colitis whereas
oral administration (either in the form of haptenated co-
lonic protein or TNBS itself) leads to the induction of sup-
pressor T cells producing TGF-
 
b
 
 and the inhibition of
colitis caused by TNBS given simultaneously by the rectal
route (6, 7). These findings in concert with similar findings
in other models establish that mucosal inflammation and/or
its prevention depend at least in part on a balance between
proinflammatory Th1 T cell responses and antiinflamma-
tory TGF-
 
b
 
 responses (1, 6–10).
While, as indicated above, TNBS has proven a useful
agent in the induction of experimental colitis, its effects on
the colon may be limited by the range of T cell responses it
is capable of inducing. In this regard, previous studies imply
that haptenating agents differ somewhat with respect to the
cell populations they address and thus differ somewhat in
the type of immune responses they induce (11–16). On this
basis, it seemed possible that administration of other hap-
tenating agents per rectum to mice might elicit a different
type of colitis. An additional reason for exploring the colit-
ogenic potential of a second haptenating agent arises from
the fact that the feeding of a haptenating agent, as alluded
to above, results in antigen nonspecific suppressor T cell re-
sponses which could potentially mediate bystander suppres-
 
1
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sion of a colitis induced by an unrelated haptenating re-
agent (6, 7, 17–23). Thus, the identification of a second
colitogenic haptenating reagent would allow one to test the
possibility that the feeding of a haptenating agent could
nonspecifically suppress (treat) colitis occurring in humans.
In this study we explored these possibilities by studying
the colitogenic potential of the “classical” haptenating
agent, oxazolone (24, 25). We found that oxazolone at the
dose administered elicited a very different colitis than that
obtained with TNBS administration in that it induced a
colitis involving only the distal half of the colon and had
histologic features resembling ulcerative colitis (UC) rather
than Crohn’s disease. In addition, oxazolone colitis is IL-4–
driven rather than IL-12–driven, is prevented by the ad-
ministration of anti–IL-4, and is exacerbated by the admin-
istration of anti–IL-12. Finally, we found that per rectal
administration of oxazolone, in contrast to TNBS, induces
a TGF-
 
b
 
 response which plays an important role in limit-
ing the inflammation both in extent and in time.
 
Materials and Methods
 
Induction of Colitis.
 
Colitis was studied in specific pathogen-
free, 5–6-wk-old male SJL/J mice obtained from the National
Cancer Institute (NCI, National Institutes of Health [NIH], Be-
thesda, MD) and maintained in the National Institute of Allergy
and Infectious Diseases (NIAID) animal facility. For induction of
colitis, mice were first lightly anesthetized with metofane (me-
thoxyflurane; Pitman-Moore, Mundelein, IL) and then 6 mg of the
haptenating agent, oxazolone (4-ethoxymethylene-2-phenyl-
2-oxazolin-5-one) (Sigma Chemical Co., St. Louis, MO), was ad-
ministered per rectum via a 3.5 F catheter equipped with a 1-ml
syringe. The catheter was inserted so that the tip was 4 cm proxi-
mal to the anal verge and the oxazolone was injected with a total
volume of 150 
 
m
 
l of a 1:1 H
 
2
 
O/ethanol mixture (50% ethanol).
To ensure distribution of the oxazolone within the entire colon
and cecum, mice were held in a vertical position for 30 s after the
injection. Control mice were administered 50% ethanol alone us-
ing the same technique.
 
Histologic Assessment of Colitis.
 
Tissues obtained at indicated
time points were fixed in 10% buffered formalin phosphate and
then embedded in paraffin, cut into sections, and then stained
with hematoxylin and eosin. Stained sections were examined for
evidence of colitis using as criteria the presence of infiltration
with lymphocyte, macrophages, or polymorphonuclear cells,
elongation and/or distortion of crypts, crypt abscesses, reduction
in goblet cell number, frank ulceration, and edema formation.
 
Isolation and Purification of Lamina Propria (LP) T Cells.
 
LP T cells
were isolated from freshly obtained colonic specimens using a
modification of the technique described by Van der Heijden and
Stok (26). Using this technique, the colonic specimens were first
washed in HBSS-calcium magnesium free and cut into 0.5-cm
pieces. They were then incubated twice, each time for 15 min in
HBSS containing EDTA (0.37 mg/ml) and dithiothreitol (0.145
mg/ml) at 37
 
8
 
C. The tissue was then digested further in RPMI
containing collagenase D (400 U/ml) and DNase I (0.01 mg/ml)
(both obtained from Boehringer Mannheim Biochemicals, India-
napolis, IN) in a shaking incubator at 37
 
8
 
C. The LP cells released
from the tissue were then resuspended in 100% Percoll, layered un-
der a 40% Percoll gradient (Pharmacia Biotech AB, Uppsala, Swe-
den), and spun at 1,800 rpm to obtain the lymphocyte-enriched
population accumulating at the 40–100% interface. Finally, the
lymphocyte-enriched population was further purified by negative
selection using an Isocell mouse T cell isolation column (Pierce
Chemical Co., Rockford, IL). The resultant T cell population,
when analyzed by flow cytometry, using a FACScan
 
Ò
 
 (Becton
Dickinson, Sunnyvale, CA), was shown to be composed of
 
.
 
90% CD3
 
1
 
 T cells.
 
Isolation and Purification of Spleen T Cells.
 
For isolation of spleen
T cells, spleens were aseptically removed. Cells were dispersed in
1
 
3
 
 PBS by applied pressure to spleen tissue. The dispersed sple-
nocytes were then filtered through a 100-
 
m
 
m filter and depleted
of RBCs by hypotonic lysis with ACK lysing buffer (Biofluids Inc.,
Rockville, MD) using a standard technique (27). The cells were
then layered on a 40–100% Percoll gradient and spun at 1,800
rpm to obtain the lymphocyte-rich cells at the 40–100% interface.
The cells were further purified by negative selection using a
mouse T cell isolation column as described above. The resultant
T cell population when analyzed by flow cytometry was shown
to be composed of 
 
.
 
90% CD3
 
1
 
 T cells.
 
Culture of LP T Cells and Spleen T Cells for Assay of Cytokine
Production.
 
Culture of LP T cells and spleen T cells was gener-
ally performed using complete medium consisting of RPMI 1640
(Whittaker M.A. Bioproducts, Inc., Walkersville, MD) supple-
mented with 3 mM 
 
l
 
-glutamine, 10 mM Hepes buffer, 10 
 
m
 
g/ml
gentamycin, 100 U/ml each of penicillin and streptomycin
(Whittaker M.A. Bioproducts, Inc.), 0.05 mM 2-ME, and 10%
by volume FCS (Sigma Chemical Co.). When cells were cultured
for evaluation of TGF-
 
b
 
 production, serum-free media supple-
mented with 1% nutridoma-SP (Boehringer Mannheim Bio-
chemicals) were used. To measure cytokine production 10
 
6
 
 LP T
cells or spleen T cells purified as described above were loaded
into uncoated culture wells (to measure production by unstimu-
lated cells) or wells coated with murine anti-CD3
 
e
 
 antibody
(clone 145-2C11; PharMingen, San Diego, CA) and 1 
 
m
 
g/ml
soluble anti-CD28 (clone 37.51; PharMingen) (to measure pro-
duction by stimulated cells) and cultured for 48 h (or 60 h in the
case of TGF-
 
b
 
). The culture supernatants were then harvested
and assayed for cytokine concentration by ELISA. The culture
plates used in these studies were 24-well Costar plates (Costar
Corp., Cambridge, MA); coating of these plates with anti-CD3
antibody was accomplished by exposing wells to a solution con-
taining anti-CD3
 
e
 
 antibody (10 
 
m
 
g/ml) in carbonate buffer (pH
9.6) overnight at 4
 
8
 
C.
 
ELISA Assays.
 
Cytokine concentrations (except for TGF-
 
b
 
)
were determined by commercially available specific ELISA assays
using duo-paired murine cytokines as per the manufacturer’s rec-
ommendations (Endogen Corp., Woburn, MA) on Immulon-4,
96-well microtiter plates (Dynatech Laboratories, Inc., Chantilly,
VA). TGF-
 
b
 
 concentrations were determined using the Predicta
TGF-
 
b
 
 ELISA assay (Genzyme Corp., Cambridge, MA). Optical
densities were measured on a Dynatech MR 5000 ELISA reader
at a wavelength of 490 nm.
 
Treatment of Mice with Anticytokine Antibodies.
 
Mice were ad-
ministered various anticytokine antibodies via intraperitoneal in-
jection at the time of disease induction with oxazolone. Rat anti–
mouse IL-4 (3 mg per dose), murine anti–human TGF-
 
b
 
1,2,3 (1
mg per dose), and rat anti–mouse IL-12 (2 mg per dose) as well as
isotype control (rat IgG2a) were used. Anti–IL-4 consisted of the
monoclonal antibody produced from the 11B11 hybridoma cell
line donated by Dr. William Paul (Laboratory Immuno-regula-
tion, NIAID, NIH); this antibody was purified from ascites fluid
produced in nude mice by precipitation in 50% saturated ammo-
nium sulfate and then dialyzed overnight as per protocol (28). 
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Figure 1. Wasting disease in mice with oxazolone colitis. Intrarectal
administration of oxazolone induces rapid onset of severe bloody diarrhea
and wasting disease. Shown are weight changes over a 10-d period occur-
ring in normal SJL/J control mice treated with 50% ethanol alone, and
SJL/J mice treated with oxazolone in 50% ethanol. Data are from one
representative experiment (out of a total of three experiments). Each
point represents average weight data pooled from five mice. Standard er-
rors are indicated.
 
Anti–TGF-
 
b
 
 consisted of the l.D11.6 monoclonal antibody pur-
chased in purified form from the Genzyme Corp. Anti–IL-12
consisted of the monoclonal antibody produced by the C17.8 hy-
bridoma cell line supplied by Dr. G. Trinchieri (Wistor Institute,
Philadelphia, PA); this antibody was purified from ascites fluid
produced in nude mice and was purified using E-Z-SEP purifica-
tion kits (Middlesex Sciences, Inc., Foxborough, MA) according
to manufacturer’s protocol. Control rat IgG2a was obtained from
Jackson ImmunoResearch (West Grove, PA).
 
Results
 
Intrarectal Administration of Oxazolone Induces a UC-like
Colonic Inflammation in SJL/J Mice.
 
In previous studies we
and others have shown that the administration of the hap-
tenating agent TNBS induces an IL-12–driven, Th1 T cell
colitis resembling Crohn’s disease (1, 6, 7, 29, 30). In stud-
ies directed at exploring if similar disease is obtained with
other haptenating agents, we subjected SJL/J mice to in-
trarectal administration of oxazolone (6 mg, dissolved in
50% ethanol), a haptenating agent that does not cross-react
with TNBS (12, 13, 15, 23). As shown in Fig. 1, SJL/J
mice so treated reproducibly developed a rapid onset colitis
marked by weight loss and diarrhea peaking by day 2 after
oxazolone administration and leading to death of 50% of
the mice by day 4. Thereafter, surviving mice at days 4–7
after oxazolone administration slowly increased their weight
and by days 10–12 the majority of the mice were free of
diarrhea and appeared healthy.
The above clinical picture of oxazolone colitis is vastly
different from TNBS colitis, a colitis with a more gradual
onset that peaks much later (7 d after induction) and is
more persistent. The two diseases also differ on the macro-
scopic and microscopic levels. Thus, as shown in Fig. 2, on
macroscopic examination of oxazolone colitis at 48 h after
oxazolone administration, a severe hemorrhagic colitis which
remarkably involves only the distal 50% of the bowel is ob-
served; this is in contrast to TNBS colitis in which inflam-
mation involving the entire length of the bowel is seen. In
addition, as shown in Fig. 3, on microscopic examination
of involved colon of oxazolone-treated mice (again at 48 h)
a superficial inflammation characterized by the presence of
epithelial cell loss and patchy ulceration, pronounced de-
pletion of mucin producing–goblet cells, and reduction of
the density of the tubular glands is present. In addition, in
the LP, a mixed inflammatory cell infiltrate consisting of
lymphocytes and granulocytes (the latter consisting mostly
of neutrophils and, to a lesser extent, eosinophils) associ-
ated with an exudation of cells into the bowel lumen is ob-
served. Finally, the submucosal layer displays marked
edema with few inflammatory cells, while in the outer
muscle layer one sees little or no evidence of inflammation
at all. The foregoing changes in the involved areas of the
colon are continuous, but end abruptly in mid-colon and
in the noninvolved colon a normal microscopic appear-
ance, i.e., no inflammation, is seen. These various changes
are in obvious contrast to those found in TNBS colitis
where one observes a transmural inflammation involving all
layers of the bowel wall that is not associated with the pres-
ence of cellular exudation or the presence of significant
numbers of neutrophils or eosinophils.
The colons of mice killed after the inflammation had
clinically subsided (at 10 d after intrarectal administration of
oxazolone) showed some evidence of the earlier presence
of inflammation. On microscopic analysis of the colonic
tissue, one could see evidence of a resolving inflammatory
process, including the presence of epithelial regeneration
(mitotic figures), reappearance of goblet cells, and a residual
Figure 2. Macroscopic changes of colons in hapten-treated mice. Pho-
tographs of dissected large intestine of (A) normal SJL/J control mouse
treated with 50% ethanol, (B) SJL/J mouse treated with oxazolone in 50%
ethanol 2 d after initial rectal administration, and (C) appearance of colons
of mice with TNBS-induced colitis 7 d after intrarectal administration.
The colons of oxazolone-treated mice display a hemorrhagic edematous
colon limited to the distal half of the colon. This is in contrast to colons in
TNBS-treated mice which display an inflammation of the entire colon. 
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Figure 3. Histologic analysis of the colons from SJL/J mice with hapten-induced colitis and control mice. (A) Photomicrograph of hematoxylin and eosin–
stained (H/E) paraffin section of distal colon (3100) from an oxazolone-treated mouse on day 2. Significant edema with inflammatory infiltrates localized to
the superficial mucosal layer is present. (B) H/E-stained section of colon (3100) from a TNBS-treated mouse at 7 d after intrarectal administration: a severe
transmural colitis with bowel wall thickening is seen. (C) Photomicrograph of H/E-stained section of colon (3150) from an oxazolone-treated mouse show-
ing the presence of superficial hemorrhage, ulceration, distortion of the crypts, loss of goblet cells, and mucin depletion. (D) High-power micrograph of
cross-section of H/E-stained section of colon (3400) of an oxazolone-treated mouse, showing a mixed lymphocytic infiltrate localized to the superficial lay-
ers of the mucosa and the presence of a luminal cellular exudate. (E) Photomicrograph of H/E-stained cross-section from the proximal colon (3100) of an
oxazolone-treated mouse showing only a small amount of mucosal edema and lymphocytic infiltrate. (F) Photomicrograph of H/E-stained cross-section of
normal control (3100) colon 2 d after ethanol administration. 
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inflammatory infiltrate consisting mainly of lymphocytes,
but few if any granulocytes. Again, this inflammatory cell
infiltrate was confined to the superficial layer of the mucosa
and did not involve the outer, muscle layer (data not
shown).
Taken together, these macroscopic and microscopic his-
tologic features of oxazolone colitis are highly reminiscent
of the features of the human inflammatory bowel disease,
UC, and thus differ greatly from TNBS colitis, which more
closely resembles Crohn’s disease.
 
The Colonic Inflammation Characteristic of Oxazolone Colitis
Is Associated with the Presence of T Cells Having a Th2 T Cell
Profile.
 
To characterize the nature of the immune re-
sponse in oxazolone colitis, we extracted T cells from in-
flamed LP and spleen specimens (at 48 h after oxazolone
administration) and determined their capacity to secrete cy-
tokines after stimulation with anti-CD3/anti-CD28 anti-
bodies in vitro as described in Materials and Methods. As
shown in Fig. 4 
 
A
 
, LP T cells (as well as spleen T cells) of
 
mice with oxazolone colitis manifested an 
 
z
 
10-fold in-
crease in spontaneous (unstimulated) IL-4 production and a
5-fold increase in anti-CD3/anti-CD28–induced IL-4 pro-
 
duction as compared with control mice (
 
P 
 
, 
 
0.01). In ad-
dition, as shown in Fig. 4 
 
B
 
, mice with oxazolone colitis
demonstrated a 
 
.
 
10-fold increase in unstimulated produc-
tion of IL-5 and a 3-fold increase in anti-CD3/anti-CD28–
induced production of IL-5 as compared with control mice
(
 
P 
 
, 
 
0.05). In contrast, as shown in Fig. 4 
 
C
 
, LP T cells (as
well as spleen T cells) of mice with oxazolone colitis mani-
fested no increase in unstimulated or stimulated production
of IFN-
 
g
 
 as compared with cells from control mice (
 
P 
 
.
 
0.05). These data thus show that oxazolone colitis is associ-
ated with the presence of LP cells that are strongly skewed
toward production of Th2 cytokines.
In further studies we compared cytokine secretion ex-
hibited by LP T cells isolated from inflamed distal colon
with T cells isolated from noninflamed proximal colon. As
shown in Fig. 5, whereas anti-CD3/CD28–induced T cells
from inflamed areas produced increased amounts of IL-4 as
shown above (
 
P 
 
, 
 
0.01), T cells from noninflamed areas
produce levels of IL-4 similar to that of control T cells (
 
P 
 
.
 
0.05). It should be noted, however, that the T cells from
the uninflamed tissue were not completely normal in that
they secreted an increased amount of IL-4, as compared
with control colonic T cells when cultured in the absence
of stimulants (
 
P 
 
, 
 
0.01).
 
Oxazolone-induced Colitis Is Associated with Increased Produc-
 
tion of the Suppressor Cytokine TGF-
 
b
 
.
 
In previous studies
of experimental colitis associated with a Th1 T cell re-
sponse (such as TNBS colitis) it was shown that the T cell
response and thus the colitis were counterregulated by the
presence of T cells producing TGF-
 
b
 
 (6–10). On this basis,
we measured the capacity of purified LP T cells from
whole colon and spleen specimens of mice with oxazolone
colitis to produce TGF-
 
b
 
. As shown in Fig. 6 
 
A
 
, T cells of
such mice (either LP T cells or spleen T cells) exhibited a
15-fold increase in TGF-
 
b
 
 production when cultured
without stimulation or a 30-fold increase in TGF-
 
b
 
 pro-
duction when cultured in the presence of anti-CD3/
CD28, as compared with cells from control mice (
 
P 
 
,
Figure 4. Cytokine production of stimulated and unstimulated LP and spleen T cells in oxazolone-induced colitis. LP T and spleen T cells were iso-
lated from oxazolone and control (ethanol-treated) mice on day 2 and cultured for 48 h in the presence or absence of anti-CD3 and anti-CD28 (see Ma-
terials and Methods). Culture supernatants were analyzed for concentrations of IL-4, IL-5, and IFN-g secretion by specific ELISA. Data shown represent
pooled values from three independent experiments. Standard errors are indicated.
Figure 5. In vitro IL-4 secretion by LP T cells extracted from proximal
(noninvolved) and distal (involved) colons of mice with oxazolone-
induced colitis as compared with control (ethanol-treated) mice. Data
shown represent pooled values from three independent experiments.
Standard errors are indicated. 
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0.01). In addition, as shown in Fig. 6 
 
B
 
, purified LP T cells
isolated from the uninflamed proximal colonic tissue pro-
duced fourfold more TGF-
 
b in the unstimulated state and
almost twofold more TGF-b in the stimulated state than T
cells isolated from inflamed distal colon tissue (P , 0.05).
Cytokine Production of LP T Cells of Mice with Oxazolone
Colitis During the Resolution Phase of the Colitis. In a fur-
ther series of studies of cytokine production of T cells from
mice with oxazolone colitis, we determined the cytokines
produced by LP T cells obtained from mice who had sur-
vived oxazolone colitis and were in a resolution phase of
the inflammation (at 10 d after oxazolone administration
per rectum). As shown in Fig. 7, LP T cells from such
mice, when cultured in vitro with anti-CD3/CD28, ex-
hibited IL-4 production comparable with that of T cells
from control mice (P . 0.05), but exhibited IL-5 produc-
tion as high as that seen at the peak of the inflammation
(i.e., at 48 h) (P , 0.01). In addition, while TGF-b pro-
duction by T cells obtained from the distal colons of mice
with resolving colitis compared with that by T cells from
colons with acute colitis was diminished, it was still twofold
higher than TGF-b production by control LP T cells when
cultured in vitro with anti-CD3/CD28 (P , 0.05). Finally,
T cells isolated from the proximal, noninvolved colons of
mice with resolving colitis continued to secrete high levels
of TGF-b (282 pg/ml in the unstimulated state, 5,316 pg/ml
in the stimulated state).
Treatment of Oxazolone Colitis with Various Anticytokine
Antibodies. In a final series of studies we sought to evalu-
ate the role of elevated IL-4 and TGF-b secretion in the
Figure 6. (A) TGF-b secretion of unstimulated and stimulated LP and spleen T cells (LP T cells isolated from whole colons of mice with oxazolone
colitis). LP T and spleen T cells were isolated from oxazolone and control (ethanol-treated) mice on day 2, cultured for 48 h in the presence or absence
of anti-CD3 and anti-CD28, and culture supernatants were analyzed for concentration of TGF-b secretion by specific ELISA. Data shown represent
pooled values from three independent experiments. Standard errors are indicated. (B) In parallel experiments, purified LP T cells were extracted from
proximal (noninvolved) and distal (involved) colons of mice with oxazolone colitis and compared with control (ethanol-treated) mice for TGF-b secre-
tion. Data shown represent pooled values from three independent experiments. Standard errors are indicated.
Figure 7. Cytokine production by LP T cells from resolving oxazolone colitis. LP T cells isolated from the distal colons of mice with oxazolone colitis
and control ethanol-treated mice at 10 d after intrarectal administration were stimulated in vitro as indicated in the legend to Fig. 4. Culture supernatants
were assayed for IL-4, IL-5, and TGF-b by specific ELISA. Data shown represent pooled values from three independent experiments. Standard errors are
indicated.1935 Boirivant et al.
induction and resolution of oxazolone colitis by the sys-
temic coadministration of antibodies to these cytokines and
to an inducer of Th1 responses, IL-12. Accordingly, we ad-
ministered anti–IL-4 antibody (3 mg), anti–TGF-b (1 mg),
anti–IL-12 (2 mg), or control rat IgG (1 mg) intraperito-
neally to mice at the time of induction of oxazolone colitis
with intrarectal oxazolone administration and then noted
the effects of these treatments on the course of oxazolone
colitis and on cytokine production. As shown in Fig. 8,
while the mice that had received anti–IL-4 lost weight dur-
ing the first 24 h after oxazolone administration, they
quickly regained the lost weight and were near baseline
weight within 4 d of oxazolone/antibody administration; in
contrast, mice that had received anti–TGF-b or anti–IL-12
manifested a weight loss pattern similar to or more severe
than that exhibited by the mice that had been administered
control IgG.
Macroscopic appearance of the colons of the mice in the
various treatment groups is depicted in Fig. 9. While the
colons from the anti–IL-4–treated mice were similar in ap-
pearance to that of the control ethanol-treated mice, the
colons from the anti–TGF-b–treated mice revealed a se-
vere colitis now involving the entire length of the colon,
not just the distal half, as in untreated oxazolone colitis.
The effects of anti–IL-12 varied; 50% of the mice mani-
fested no change in the distal colitis seen after oxazolone
administration whereas the other half displayed a colitis
now involving the entire colon.
The above findings concerning the effects of antibody
treatment on the development of oxazolone colitis corre-
lated well with antibody treatment–induced changes in cy- tokine secretion. Thus, as shown in Fig. 10, administration
of anti–IL-4 to mice undergoing induction of oxazolone
colitis was, as expected, associated with a great reduction in
IL-4 and TGF-b production by isolated colonic (lesional)
T cells, as compared with cells obtained from untreated
mice or mice administered control IgG. On the other
hand, administration of anti–TGF-b to mice undergoing
induction of oxazolone colitis was associated with an ex-
pected reduction in TGF-b production, but a continued
increased level of IL-4 production. However, such treat-
ment had no effect on IFN-g production, i.e., such pro-
duction remained undetectable (data not shown). Finally,
administration of anti–IL-12 to mice undergoing induction
of oxazolone colitis was also associated with enhanced pro-
duction of IL-4, but no change in TGF-b secretion.
The above “clinical” and cytokine data, taken together,
strongly suggest that IL-4 has a primary proinflammatory
role in the development of oxazolone colitis, whereas
TGF-b has an important counterregulatory role in disease
induction and the extent of colon involved with disease.
Discussion
Oxazolone colitis, the murine colitis described here, is a
new form of experimental colitis that is easily distinguish-
able from the colitis produced by the intrarectal administra-
tion of another contactant, TNBS, or indeed most other
Figure 8. Anti–IL-4 antibodies can prevent the onset of oxazolone
colitis. Weight changes in SJL/J mice who received intrarectal oxazolone
administration and then treated with either rat IgG control Ab, anti–
TGF-b mAb, or anti–IL-12 mAb. After initial reduction in body weight
in all groups at day 1, the mice treated with anti–IL-4 showed a signifi-
cant increase in body weight, whereas mice treated with either IgG con-
trol Ab, anti–TGF-b, or anti–IL-12 continued to lose body weight. Each
point represents pooled data from five mice. Standard errors are indicated.
Figure 9. Macroscopic appearance of colons obtained from (A) control
(ethanol-treated) mice; SJL/J mice who received intrarectal oxazolone or
intrarectal oxazolone plus (B) IgG control Ab; (C) anti–IL-4; (D) anti–
TGF-b mAb; or (E) anti–IL-12 mAb (all antibodies were administered
intraperitoneally). Mice treated with anti–IL-4 mAb showed a significant
resolution in inflammation, whereas mice treated with anti–TGF-b reveal
a severe colitis that now involves the entire colon. Colons from one rep-
resentative experiment out of two are shown.1936 Induction of Th2 Experimental Colitis
forms of experimental colitis. First, it is a rapid onset in-
flammation that peaks within a few days of oxazolone ad-
ministration and leads to wasting and bloody diarrhea re-
sulting either in the death of the mouse or complete
recovery. Thus, it is different from TNBS colitis, which is a
more slowly developing intestinal inflammation that peaks
1 wk after TNBS administration and that tends to persist in
surviving mice. Second, the macroscopic and microscopic
changes observed in oxazolone colitis and TNBS colitis are
very different; oxazolone colitis is marked by inflammation
strictly limited to the distal half of the colon, whereas
TNBS colitis is a pan-colitic. In addition, at the micro-
scopic level the inflammation of oxazolone colitis is rela-
tively superficial and is characterized by ulceration, a cellular
exudate, and a mixed inflammatory infiltrate of lympho-
cytes, granulocytes, and eosinophils. TNBS colitis, on the
other hand, is a full-thickness inflammation which is associ-
ated with a dense, lymphocyte/macrophage infiltration oc-
casionally arrayed as a granuloma. Third, and perhaps most
importantly, the nature of the immune response in the two
colitides are different. In oxazolone colitis the T cell re-
sponse is an IL-4–driven Th2 T cell response which is
marked by elevated IL-4/IL-5 production and normal
(low) IFN-g production and which is prevented by the
systemic coadministration of anti–IL-4. In contrast, in
TNBS colitis an IL-12–driven Th1 T cell response prevails,
marked by an elevated IFN-g response and an inflamma-
tion that is treated by the administration of anti–IL-12 (1).
These characteristics of oxazolone colitis and TNBS colitis
can be compared with those of human UC and Crohn’s dis-
ease, the two major forms of human inflammatory bowel
disease. Thus, in previous studies conducted by ourselves
and others, it has been shown that human UC is associated
with elevated IL-5 secretion and normal IFN-g secretion;
nevertheless, it cannot as yet be called a Th2 inflammation
because it is not associated with elevated IL-4 secretion, the
usual driving force of Th2 responses. On the other hand, es-
tablished Crohn’s disease is quite definitely a Th1 inflamma-
tion since IL-12 and IFN-g secretion is elevated and there is
no increase in either IL-4 or IL-5 secretion (2–5, 31). On
this basis, it seems reasonable to suggest that oxazolone coli-
tis is a murine model related to but not identical to UC,
whereas TNBS colitis is a model related to Crohn’s disease.
Most experimental murine models of colitis studied thus
far have been shown to be more like TNBS colitis than ox-
azolone colitis, i.e., IL-12–driven Th1 T cell–dependent
inflammatory responses that, as mentioned, histopathologi-
cally resemble human Crohn’s disease. This is true of colitis
models with quite disparate immune defects such as the
colitis occurring in SCID mice reconstituted with normal
(naive) T cells, as well as IL-10 and IL-2 knockout mice (32–
34). In addition, it is also true of a recently described model
of spontaneously occurring intestinal inflammation occurring
in the SAMP1/YIT strain of mice that is unique because it
involves the small intestine rather than the colon (35). The
existence of these various models implies that a number of
immunologic conditions occurring in both normal mice and
mice with genetic defects of immune function can give rise
to a final common pathway: the unregulated production of
IL-12 and the resulting development of a Crohn’s disease–
like intestinal inflammation. Conversely, it implies that the
skewed Th1 response occurring in the intestine of patients
with Crohn’s disease could result from any of several immu-
nologic abnormalities whose only commonality is that they
ultimately result in a dysregulated Th1 response.
An important and relevant exception to the above rule
that experimental colidites in mice are usually the result of
Th1 inflammatory responses is inherent in the characteris-
tics of oxazolone colitis as well as the colitis developing in
TCR-a chain knockout mice. Thus, as documented here
and as reported previously, in both of these situations an
IL-4–driven Th2 colitis develops that histopathologically
more closely resembles UC than Crohn’s disease (36–38).
The existence of these models implies that a number of dif-
ferent immunologic conditions can also lead to another fi-
nal common pathway, namely the unregulated induction of
Figure 10. Cytokine production of stimulated and unstimulated LP T cells in oxazolone-induced colitis mice treated with rat IgG control Ab, anti–IL-4,
anti–TGF-b mAb, or anti–IL-12 mAb at the time of intrarectal oxazolone administration. LP T were isolated on day 3, cultured for 48 h in the presence
or absence of anti-CD3 and anti-CD28, and culture supernatants were analyzed for concentration of (A) IL-4 and (B) TGF-b by specific ELISA. Data
from one representative experiment out of two are shown.1937 Boirivant et al.
Th2 T cells. In addition, these two latter models, when
considered in conjunction with the Th1 models, provide
additional support for the view that immunologic condi-
tions leading to Th2 and Th1 dysregulation are the basis of
UC and Crohn’s disease, respectively.
The colitis occurring in TCR-a chain knockout mice,
in that it is immunologically similar to oxazolone colitis,
bears further discussion. TCR-a chain knockout mice de-
velop T cells with low expression of TCRs comprised of
b-chain homodimers. Therefore, their tendency to de-
velop Th2 responses may be related to necessarily aberrant
interactions with APCs. The colitis that occurs in such
mice is a slowly developing disease that appears to originate
in the appendiceal tissue and thus initially involves the cecal
area of the colon exclusively; ultimately, however, it in-
volves the entire colon and then persists as a chronic in-
flammation (36–40). This pattern of inflammation differs
from that seen in oxazolone colitis, since the latter is a distal
rather than a proximal colitis and is an acute but ultimately
self-limited disease (provided the mice survive the period
of acute inflammation). The reason for these differences
awaits further analysis of the cytokine milieu present in the
two models, particularly after the inflammation becomes
well established. One possibility, based on the fact that the
locus and course of oxazolone colitis probably depend on
the nature of the elicited TGF-b response, is that ox-
azolone colitis and the colitis of TCR-a chain knockout
mice are associated with qualitatively and quantitatively
different TGF-b responses.
One of the striking features of oxazolone colitis is that it
is associated with high LP T cell production of TGF-b that
is greater in proximal, uninvolved colons than in the distal,
involved colon. This, plus the fact that anti–TGF-b admin-
istration to mice at the time of intrarectal oxazolone ad-
ministration leads to pan-colitis (i.e., involvement of the
normally uninvolved proximal colon), strongly suggests
that the TGF-b response in the proximal colon prevents
disease in this segment of bowel, whereas the response in
the distal colon, while still relatively high, is not sufficient
to prevent disease in this segment of the bowel; it is thus
the colonic TGF-b gradient that explains the proximal dis-
tribution of disease in oxazolone colitis. In addition, it
seems likely that the short-lived nature of the distal inflam-
mation in oxazolone colitis is attributable to the still rela-
tively high TGF-b response in this area of the colon and
thus the ability of the latter response to eventually over-
come the distal inflammation. On the basis of these findings
in oxazolone colitis, it is reasonable to suggest that the gen-
erally distal distribution of inflammation in UC is also due
to a TGF-b gradient in the human colons. However, this
suggestion runs counter to recent findings showing that
TGF-b synthesis is higher in the inflamed areas of the UC
colon than in uninflamed areas (41). One possible resolu-
tion of this discrepancy lies in the fact that in the study
cited TGF-b synthesis was measured at the mRNA level in
whole colonic biopsies; thus TGF-b produced by all cells
was measured and the gradient referred to above may only
apply to T cell production of this cytokine.
The high TGF-b response in oxazolone colitis contrasts
with the virtually nil TGF-b response in TNBS colitis (un-
less TNBS is concomitantly given by mouth in the form of
haptenated protein) (6, 7). These very different TGF-b re-
sponses in oxazolone and TNBS colitis are at least partially
explained by recent studies of the differentiation of naive T
cells into TGF-b–producing T cells in primary and sec-
ondary cultures (42). In these studies it was shown that Th1
responses (i.e., IL-12 and IFN-g production) inhibit the
differentiation of TGF-b–producing cells whereas Th2
responses (IL-4 production) favor such differentiation.
Whether or not these effects are completely independent is
still somewhat unclear, but, in any case, they may explain
the fact that a Th2 T cell–induced inflammation such as
oxazolone colitis is associated with a high TGF-b response.
One question that remains to be answered concerning
the high TGF-b response in oxazolone colitis is why this
response did not prevent the inflammation from develop-
ing in the first place, in that much lower TGF-b responses
induced by the feeding of TNP haptenated–protein to
mice prevents the induction of TNBS colitis (6). The an-
swer to this question may lie in the relative ability of TGF-b–
producing T cells to suppress Th1 responses and Th2 re-
sponses: it is possible that Th2 responses are resistant to
TGF-b–mediated suppression, whereas Th1 responses are
susceptible to such suppression. Indirect evidence in favor
of this possibility is that certain immune responses normally
supported by Th2 cytokines such as humoral IgA responses
actually require TGF-b and are not suppressed by the latter
except at high TGF-b concentrations (43).
The induction of a Th2-mediated colitis by the rectal
administration of oxazolone (at the doses used) and a Th1-
mediated colitis by the rectal administration of TNBS raises
the fundamental question as to the relation of the nature of
the stimulating antigen to the course of T cell differentia-
tion. At the moment this question can only be answered in
general terms by the suggestion that the initial interaction
between mucosal APCs presenting TNBS or oxazolone to
T cells recognizing these haptens results in preferential ex-
cretion of IL-12 in the case of TNBS and IL-4 in the case
of oxazolone. Whether this relates to antigen affinity for
available T cell receptors and subsequent patterns of ex-
pression of CD40L and/or B7 is unknown and awaits fur-
ther study. Nevertheless, this dichotomy does suggest that
whether or not an individual susceptible to inflammatory
bowel disease develops UC or Crohn’s disease may to
some extent depend on factors relating to the nature of the
initial inducing antigen.
In summary, oxazolone colitis is a new mucosal model of
colitis that is an IL-4–driven, Th2 inflammation that has
features resembling the human disease, UC. This colitis is
regulated in a unique manner by TGF-b production, an
observation that may have significance to the factors that
regulate its human counterpart.1938 Induction of Th2 Experimental Colitis
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